3-Methylpiperidin-4-one → 4-(2-hydroxypropan-2-yl)-N-(7-(3-methyl-4-oxopiperidin-1-yl)pyrazolo[1,5-a]pyrimidin-5-yl)benzamide
Reaction equation
Cl[C:2]1[N:7]2[N:8]=[CH:9][CH:10]=[C:6]2[N:5]=[C:4]([NH:11][C:12](=[O:23])[C:13]2[CH:18]=[CH:17][C:16]([C:19]([OH:22])([CH3:21])[CH3:20])=[CH:15][CH:14]=2)[CH:3]=1.[CH3:24][CH:25]1[C:30](=[O:31])[CH2:29][CH2:28][NH:27][CH2:26]1>CN1C(=O)CCC1.CS(C)=O.CO>[OH:22][C:19]([C:16]1[CH:17]=[CH:18][C:13]([C:12]([NH:11][C:4]2[CH:3]=[C:2]([N:27]3[CH2:28][CH2:29][C:30](=[O:31])[CH:25]([CH3:24])[CH2:26]3)[N:7]3[N:8]=[CH:9][CH:10]=[C:6]3[N:5]=2)=[O:23])=[CH:14][CH:15]=1)([CH3:21])[CH3:20]Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 3
Procedure
A solution of N-(7-chloropyrazolo[1,5-a]pyrimidin-5-yl)-4-(2-hydroxypropan-2-yl)benzamide (2D, 50 mg, 0.151 mmol) and 3-methylpiperidin-4-one (34 mg, 0.302 mmol) in NMP (0.950 mL) was stirred at 85° C. overnight. After cooling to room temperature, the mixture was diluted with a few drops of DMSO and methanol, and was then purified by preparatory HPLC, 30-55% (MeCN/H2O gradient+0.01% TFA). Lyophilization of the combined fractions gave the titled compound as a white solid (34 mg, 56%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.02 (d, J=6.57 Hz, 3 H) 1.46 (s, 6 H) 2.74-2.97 (m, 2 H) 3.30 (t, J=11.87 Hz, 1 H) 3.57-3.69 (m, 1 H) 4.56-4.70 (m, 2 H) 6.38 (d, J=2.27 Hz, 1 H) 7.48 (s, 1 H) 7.60 (d, J=8.59 Hz, 2 H) 8.00 (d, J=8.59 Hz, 2 H) 8.13 (d, J=2.27 Hz, 1 H) 10.93 (s, 1 H). ESI-MS: m/z 408.2 (M+H)+.
Workup
- customwas then purified by preparatory HPLC, 30-55% (MeCN/H2O gradient+0.01% TFA)
Sources & evidence
- ORD record
- ord-075062ce3a4c4773a30c6b7c99216dc7
- Source dataset
- uspto-grants-2013_06
- Patent number
- US08461163B2
Reaction notes
Loading…